Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Clearance of C2N Diagnostics' PrecivityAD2 Blood Test Advances Precision Medicine ...

20 August 2026 · By · Wire by Fusion42

Published

20 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 20 August 2026 · Fusion42 review

The FDA has cleared C2N Diagnostics' PrecivityAD2 blood test, advancing precision medicine for Alzheimer's disease diagnosis by providing a less invasive and more accessible biomarker test option.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 13 sources have reported it between 20 Aug 2026 and 26 Sep 2026.

◆ ◆ The Wire takeaway

You face new opportunities as blood-based Alzheimer's testing gains regulatory approval, reducing barriers to market and patient access. Adjust your clinical plans now to integrate more scalable and less invasive diagnostic methods.

◆ Coverage

13 sources · first reported 20 Aug 2026 · latest 26 Sep 2026

◆ Related on Wire

◆ Topics

Diagnosticsfda-clearancealzheimersprecision-medicineblood-testdiagnostics